Genome modification has become an essential part of most biotech’s research and development pipelines. Two general approaches are commonly used: electroporation of nuclease and nucleic acids i.e., Cas9 RNPs, or transfection of vectors expressing nucleases, targeting nucleic acids and donor genetic material.
One of the major limitations of these approaches is that they take a long time to generate a usable clonal cell population. A major advantage of Yokogawa's Single Cellome™ Unit SU10 nanopipette injection system is the ability to efficiently genome edit cells at a single cell level, allowing the user to start with a clonal population and decreases cell line generation time to as fast as 3 weeks.
Key Topics:
Andrew Seeber, PhD
Director
Transition, Bio Inc
View Webinar